Diminished serotonergic innervation of adult medial prefrontal cortex after 6-OHDA lesions in the newborn rat.
The development of the serotonergic (5HT) and dopaminergic (DA) systems may contribute to the onset of psychotic disorders during late adolescence and early adulthood. Previous studies in our laboratory have suggested that these systems may compete for functional territory on neurons during development, as lesions of the serotonergic system at postnatal day 5 (P5) result in an increase in the density of dopaminergic fibers in rat medial prefrontal cortex (mPFC). In the present study, the dopaminergic system of P5 rats was lesioned with intracisternal injections of 6-hydroxydopamine (6-OHDA). Quantification of serotonin-immunoreactivity (5HT-IR) in mPFC at adulthood (P70) revealed a significant decrease in fiber density within layers II and III of the Cg3 subdivision of mPFC in lesioned rats compared to sham controls. We propose that the decrease in serotonergic fibers in mPFC in response to a neonatal depletion of dopamine may be due to the loss of a trophic effect of this system on 5HT neurons and/or fibers during development. Taken together with previous findings, our data suggest that there may be an "inverse trophic" relationship between the cortical DA and 5HT systems whereby dopamine facilitates the ingrowth of 5HT fibers, while serotonin suppresses the ingrowth of DA fibers. We present a model based on neurotrophic interactions at the cortical and brainstem levels that could potentially explain these unexpected results.
Cunningham
Miles Gregory
MG
Laboratory for Structural and Molecular Neuroscience, McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA. mcunningham@mclean.harvard.edu
Connor
Caroline Martine
CM
Zhang
Kehong
K
Benes
Francine Mary
FM
D000818:Animals; D000831:Animals, Newborn; D002450:Cell Communication / Q000502:physiology; D002454:Cell Differentiation / Q000502:physiology; D003714:Denervation; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism*; D015536:Down-Regulation / Q000502:physiology; D020439:Growth Cones / Q000378:metabolism; D007150:Immunohistochemistry; D008297:Male; D001523:Mental Disorders / Q000209:etiology / Q000503:physiopathology; D008959:Models, Neurological; D009414:Nerve Growth Factors / Q000378:metabolism*; D009434:Neural Pathways / Q000254:growth & development / Q000378:metabolism* / Q000503:physiopathology; D016627:Oxidopamine; D017397:Prefrontal Cortex / Q000254:growth & development / Q000378:metabolism* / Q000503:physiopathology; D011903:Raphe Nuclei / Q000254:growth & development / Q000378:metabolism* / Q000503:physiopathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012701:Serotonin / Q000378:metabolism*; D013565:Sympatholytics
D009414:Nerve Growth Factors; D013565:Sympatholytics; D012701:Serotonin; D016627:Oxidopamine; D004298:Dopamine